Form 4: BrainStorm Cell Therapeutics Director Option Grant

Director Menghisteab Bairu was granted 150,000 stock options in BrainStorm Cell Therapeutics Inc. (BCLI).

Summary

• Director Menghisteab Bairu received a grant of 150,000 stock options on February 26, 2026.
• The options have an exercise price of $0.70 per share.
• The options expire on February 26, 2036.
• Vesting occurs in two tranches: 50% on the grant date and 50% on the six-month anniversary.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the exercise of these options.

Risks

• Market volatility affecting the value of the underlying common stock.
• Dependence on the company's ability to maintain the director's service through the vesting period.

Future Outlook

The filing does not provide forward-looking guidance regarding company operations or financial performance.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to incentivize leadership and retain talent during clinical development phases.

Comparison to Industry Standards

• The use of a 2014 Stock Incentive Plan is consistent with standard equity compensation structures for small-cap biotech firms.
• Vesting schedules involving immediate and six-month cliffs are common for director compensation in the industry.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of the remaining 50% of options on August 26, 2026.

Key Dates

Keywords

BCLI, BrainStorm Cell Therapeutics, Form 4, Insider Trading, Stock Options, Director Compensation